Login to Your Account

Together again, and sails-up for COLUMBUS

Under a deal that depends on Novartis AG's big, pending asset swap with Glaxosmithkline plc, the BRAF inhibitor encorafenib – stranded with Novartis since December, when the pharma giant returned MEK blocker binimetinib rights to Array Biopharma Inc. – is joining its sister at Array, and the phase III combination trial called COLUMBUS in BRAF-positive melanoma (encorafenib's fate in which had been unsure), will go on. more »

Our Habitat for All Things Science
Genome studies broaden and deepen as methods progress

TOKYO – In the nearly 12 years since the completion of the Human Genome Project, next-generation sequencing methods have made genome sequencing both faster and cheaper, leading to massive increases in the numbers of individuals who can be sequenced. Projects have gone from the Human Genome Project, to the 1,000 Genomes Project, to the announcement last week of a 100,000 Genomes Project that plans to start recruiting patients in February 2015. (See BioWorld Today, Dec. 23, 2014.)